An MDA-supported study of tadalafil, a drug that may improve blood flow to exercising muscles in people with Becker MD, is seeking 12 additional participants
Update (Nov. 9, 2012): This story has been updated to reflect that recruitment for this study ends Dec. 31, 2012.
An MDA-supported, short-term trial of the vasodilating drug tadalafil (Cialis) in teens and men with Becker muscular dystrophy (BMD) has undergone some minor restructuring and is now open to 12 additional participants.
Videos of the entire MDA-sponsored conference on Becker muscular dystrophy, held Aug. 11, 2012, in Chicago, are available on the MDA website
Videos of the entire MDA-sponsored Becker Muscular Dystrophy Conference, held in Chicago on Aug. 11, 2012, are now archived on the Conference video page.
Each presentation covers a different aspect of Becker muscular dystrophy (BMD). Below is a short summary of each video, along with the running time in minutes and seconds.
Ronald Victor admits it: He never set out to study muscular dystrophy. As an adult cardiologist specializing in hypertension (high blood pressure) and neurologic control of cardiovascular mechanisms, he’s a relative latecomer to the muscle field, but far from a reluctant one.
The vasodilating drug tadalafil (Cialis) will be tested in men with Becker muscular dystrophy to see if it improves blood flow to forearm muscles
Update (Oct. 8, 2012): This story has been updated to reflect that the tadalafil trial in BMD has been slightly revised and is now open. In June 2012, it had temporarily closed to new participants. The investigators say the revised trial design was necessary because they were unable to obtain access to the MRI machine for the time periods that were necessary in the first design.